CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells

K. Lehnus, Laura K. Donovan, X. Huang, N. Zhao, T. Warr, Geoff Pilkington, Qian An

Research output: Contribution to journalArticle

118 Downloads (Pure)


The cancer stem cell (CSC) marker CD133 is widely expressed in gliomas and employed mostly by use of the CD133/1 antibody which binds the extracellular glycosylated AC133 epitope. CD133 recognition may, however, be affected by its glycosylation pattern and oxygen tension. The present study investigates the effect of oxygen deprivation on CD133 expression and glycosylation status employing a high AC133-expressing glioblastoma multiforme (GBM) cell line, IN699. IN699 cells were cultured under normoxic (21% O2) and hypoxic (3% O2) conditions. CD133 expression was analysed by western blotting (WB), qRT-PCR, immunocytochemistry (ICC) and flow cytometry using the glycosylation-specific antibody CD133/1 and ab19898 which binds the unglycosylated intra-cellular residues of CD133. By flow cytometry, ab19898 detected 94.1% and 96.2% CD133+ cells under normoxia and hypoxia, respectively. Hypoxia significantly increased the percentage of CD133+ cells from 69% to 92% using CD133/1 (p
Original languageEnglish
Pages (from-to)1011-1017
Number of pages7
JournalInternational Journal of Oncology
Issue number3
Publication statusPublished - Mar 2013


Dive into the research topics of 'CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells'. Together they form a unique fingerprint.

Cite this